Recently, it has been evaluated in a phase II trial (SORMAIN) as a maintenance therapy and in an open-label randomized phase III trial in adult patients with FLT3-ITD (internal duplications in tandem) mutated AML, who had already undergone allogeneic hematopoietic stem cell transplantations. Here, FLT3 is linked to acute myeloid leukemia.